Blueberry expansion at Alderley Park

The Blueberry team are delighted to be moving into a larger, more spacious office area on the Alderley Park site, with views over the Cheshire plains. The move will bring the whole team together [...]

2020-09-23T12:43:59+00:00September 23rd, 2020|

Blueberry publishes latest peer-reviewed scientific paper

Today, Blueberry Therapeutics published our latest peer-reviewed scientific paper. The paper entitled “Assessment of the nail penetration of antifungal agents, with different physico-chemical properties” was published in PLoS One (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0229414) and describes our research into [...]

2020-03-03T10:03:51+00:00February 27th, 2020|

Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors

Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent Non-Executive Director, strengthening its strategic, financial and therapeutic expertise.   Dr. Howd has over 20 years’ experience in the life science sector. He has held various private and public company Executive and [...]

2020-01-15T13:12:58+00:00January 15th, 2020|

Dave Edwards joins Blueberry Therapeutics

Blueberry Therapeutics are delighted to welcome Dave Edwards as Pharmaceutical Development Director, where he is responsible for CMC aspects of the manufacture of clinical supply materials through Phase II and III studies as well as [...]

2019-07-16T09:28:46+00:00July 1st, 2019|

Diane Lee joins the Blueberry team

We are delighted to welcome Diane Lee to the Blueberry Clinical Team. Diane has over 15 years’ experience in clinical research in different settings; Clinical Research Organisations, pharmaceutical companies and academic research.  She has a [...]

2019-07-03T21:01:54+00:00June 4th, 2019|